FDA's Shorten Review Time is a Bad Sign for Puma Biotech's Controversial Cancer Drug
<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-fda.jpg" NAME"FDA's Shorten Review Time is a Bad Sign for Puma Biotech's Controversial Cancer Drug" ALT"FDA's Shorten Review Time is a Bad Sign for Puma Biotech's Controversial Cancer Drug"April…